HZC102871: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

Trial Profile

HZC102871: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

Completed
Phase of Trial: Phase III

Latest Information Update: 25 May 2017

At a glance

  • Drugs Vilanterol; Vilanterol/fluticasone furoate
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 13 Apr 2012 NCT reports actual end date as Oct 2011.
    • 09 Jan 2012 Primary endpoint 'Symptom-exacerbation-rate' was met with vilanterol/fluticasone furoate 25/100µg, but not with the 25/200µg and 25/50µg doses, according to a GlaxoSmithKline and Theravance media release.
    • 09 Jan 2012 Status changed from active, no longer recruiting to completed, according to a GlaxoSmithKline and Theravance media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top